GlobeNewswire by notified

Amlan International to Showcase Natural Mineral Technology at International Production and Processing Expo (IPPE)


CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America, is pleased to announce its participation in the International Production and Processing Expo (IPPE) January 24-26, 2023, in Atlanta, GA. Attendees will learn more about the latest in feed technology for animal protein producers that optimize gut health through three exciting TECHTalks, a new product showcase featuring Phylox®, and two poster presentations during the International Poultry Scientific Forum (IPSF). Amlan is also proud to be the exclusive sponsor of the IPPE Media Center. Amlan looks forward to welcoming a global audience of animal production professionals and sharing more about its range of products with attendees, media and other exhibitors at its booth, B5453.

Last year at IPPE, Amlan expanded its product portfolio with the launch of Phylox (available in select international markets). Phylox is a research-backed, natural alternative to anticoccidial drugs that supports gut health naturally thus improving productivity and, in turn, driving producers' profits. This year, Phylox will be highlighted during the expo’s new product showcase. Attendees can watch a video presentation to learn more about the company’s latest innovation. 

“We look forward to speaking with producers about how Phylox, a bioactive blend of antiprotozoal phytochemicals with multiple modes of action, decreases the negative production and health effects of coccidiosis,” said Dr. Wade Robey, Vice President of Agriculture, Oil-Dri, and President, Amlan International. “Phylox is natural and can be used in “no antibiotics ever” (NAE) programs, has no withdrawal requirements, and can be fed in combination with anticoccidial vaccines preventing disease breakthrough.”

“We are excited about the success of our North American portfolio, which includes Sorbiam™ and Enterotec™. The industry reaction to these products created to optimize animal gut health has been tremendous,” according to Heath Wessels, Vice President of Sales, The Americas. “Working with our key customers, our products continue to demonstrate the efficacy of our mineral-based feed additives.” 

Attendees can learn more about the latest in protein and feed technology presented during TECHTalks.

On Tuesday, January 24:

  • Dr. Marc Herpfer, VP, New Technologies, Oil-Dri Corporation of America, will present “Natural Mineral Technology as an Alternative to AGPs” in B Hall, Booth B8675 at 11:00 a.m.
  • Dr. Josh Payne, Dir. Technical Service, Poultry Guard, will present “Best Management Practices and Utilization of Clay-Based Litter Amendment for pH and Ammonia Control” in B Hall, Booth B3646 at 11:30 a.m.

On Wednesday, January 25:

  • Mike Donohue, VP, Agri Stats, Inc. will present “The Importance of 1%, The Effect of Efficiency on Sustainability and Economic Value” in B Hall, Booth B3646 at 10:00 a.m. 

TECHTalks are an excellent way for us to provide valuable information on specific technical challenges the industry is facing,” says Dr. Aldo Rossi, Vice President, Innovation and Technical Service. “We are proud of our high-quality and efficacious mineral-based feed additives for poultry and livestock, and how they can improve the quality of animal protein. We look forward to sharing our solutions with producers.”

During the International Poultry Scientific Forum (IPSF) on January 23, Amlan experts will present two posters, selected by IPSF, detailing research designed to support optimal poultry intestinal health and bring the latest production technology to producers. The presentations will be from 4:00 p.m. to 6:00 p.m.:

  • Feeding Varium® produces growth performance similar to feeding an antibiotic on-farm, by Dr. Sara (LeAnn) Johnston, Technical Service Manager, Amlan International
  • A natural coccidiostat, Phylox Feed, improves performance, intestinal lesion scores, and fecal oocyst shedding of Eimeria-infected broilers, Dr. San (Chris) Ching, Senior Research Manager, Amlan International.

Amlan is continuing to proudly celebrate its 15th anniversary of providing natural mineral-based feed additives to the industry. The Amlan brand was introduced into the feed-additive market in 2007. Vertical integration allows Amlan to leverage Oil-Dri's mineral science expertise to develop novel, natural feed additives. Oil-Dri launched its first mineral-based product, an industrial floor absorbent, in 1941, and since then has mined and processed a range of unique minerals for many applications. Oil-Dri has been active in the animal health market since the 1980s, with products that assist feed flowability and pellet binding. 

“As the proud exclusive sponsor of the IPPE Media Center, Amlan looks forward to building relationships with media from around the world,” says Reagan Culbertson, Vice President of Strategic Marketing, B2B. “We hope media professionals will visit the Media Center to work, network and visit with our experts about Amlan’s unique and exciting mineral technology.” 

For more information on Amlan International, please visit:

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process its unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Managers’ transactions9.12.2023 18:12:40 CET | Press release

December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release

Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release

Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful

Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release

At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t